RxSight (NASDAQ:RXST) Posts Earnings Results, Beats Estimates By $0.22 EPS

RxSight (NASDAQ:RXST) announced its quarterly earnings data on Wednesday. The company reported ($0.11) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.22, FiscalAI reports. The company had revenue of $33.74 million during the quarter, compared to analysts’ expectations of $32.55 million. RxSight had a negative net margin of 36.58% and a negative return on equity of 17.01%.

Here are the key takeaways from RxSight’s conference call:

• Core product sales declined 19% year over year to $27.2 million, while LAL unit volume fell 9% to 24,917 units amid competitive trialing and broader market headwinds. Gross margin excluding Alcon also decreased to 71.2% from 74.9%, primarily due to higher inventory-related costs.
• Management withdrew its full-year 2026 financial guidance, citing the need for a thorough assessment and flexibility to make potential strategic or operational changes. Formal guidance is expected to resume with the company’s fourth-quarter results in early 2027.
• The company reported a strategic collaboration with Alcon that contributed $6.5 million of second-quarter revenue and is expected to generate $30 million to $40 million in 2026 revenue, plus future milestones and royalties. RxSight ended the quarter with approximately $209 million in cash and investments, before receiving an additional $60 million upfront payment after quarter-end.
• New CEO Aziz Mottiwala plans to shift the commercial strategy from establishing broad account reach to driving deeper utilization within the existing 1,166-unit LDD installed base. The company intends to eventually double its U.S. sales team, primarily through internal resource reallocations, while improving practice workflows, physician education, and patient selection.
• Management said early third-quarter trends are encouraging, but expects continued competition, product trialing, seasonality, affordability pressures, and broader market conditions to affect results. Alcon-related revenue is expected to be limited in the third quarter, with most of the remaining 2026 contribution recognized in the fourth quarter.

RxSight Price Performance

Shares of NASDAQ:RXST traded down $0.21 during trading on Thursday, reaching $6.08. The stock had a trading volume of 1,336,943 shares, compared to its average volume of 979,532. RxSight has a 52 week low of $4.48 and a 52 week high of $13.22. The business’s 50-day moving average price is $5.29 and its 200 day moving average price is $6.67. The stock has a market capitalization of $251.69 million, a PE ratio of -5.38 and a beta of 1.13.

Analysts Set New Price Targets

Several research analysts recently issued reports on RXST shares. Bank of America dropped their price target on shares of RxSight from $8.00 to $6.50 and set an “underperform” rating for the company in a research report on Tuesday, July 7th. Wall Street Zen upgraded RxSight from a “strong sell” rating to a “sell” rating in a research note on Sunday, July 12th. Wells Fargo & Company dropped their target price on RxSight from $11.00 to $9.00 and set an “equal weight” rating for the company in a report on Thursday, May 7th. UBS Group raised their target price on RxSight from $5.50 to $6.30 and gave the stock a “neutral” rating in a research report on Thursday. Finally, Weiss Ratings lowered RxSight from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, June 11th. Two analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and three have given a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Reduce” and an average target price of $8.59.

Institutional Investors Weigh In On RxSight

Hedge funds and other institutional investors have recently bought and sold shares of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in RxSight by 6.0% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,861 shares of the company’s stock worth $552,000 after purchasing an additional 1,232 shares in the last quarter. Goldman Sachs Group Inc. increased its stake in shares of RxSight by 57.9% in the first quarter. Goldman Sachs Group Inc. now owns 310,411 shares of the company’s stock valued at $7,838,000 after buying an additional 113,767 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in shares of RxSight by 9.9% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 93,382 shares of the company’s stock valued at $2,358,000 after buying an additional 8,424 shares during the last quarter. Creative Planning bought a new position in shares of RxSight in the second quarter valued at about $207,000. Finally, Legal & General Group Plc raised its holdings in shares of RxSight by 5.0% in the second quarter. Legal & General Group Plc now owns 44,574 shares of the company’s stock valued at $579,000 after buying an additional 2,121 shares during the last quarter. 78.78% of the stock is owned by institutional investors and hedge funds.

RxSight Company Profile

RxSight, Inc is a medical technology company focused on the development and commercialization of advanced intraocular lens (IOL) systems for patients undergoing cataract surgery and lens replacement procedures. The company’s flagship product, the Light Adjustable Lens (LAL), is designed to provide customized vision correction by allowing non‐invasive post‐operative adjustments. Using ultraviolet light, surgeons can fine‐tune the lens power after implantation to achieve optimal visual outcomes, reducing reliance on glasses or contact lenses and enhancing patient satisfaction.

Founded in 2011 and headquartered in Aliso Viejo, California, RxSight has pursued regulatory clearances and market access across multiple regions.